Premium
CNS progression during vinblastine or targeted therapies for high‐risk relapsed ALK‐positive anaplastic large cell lymphoma: A case series
Author(s) -
Ruf Stephanie,
Hebart Holger,
Hjalgrim Lisa Lyngsie,
Kabickova Edita,
Lang Peter,
Steinbach Daniel,
Schwabe Georg C.,
Woessmann Wilhelm
Publication year - 2018
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.27003
Subject(s) - crizotinib , medicine , anaplastic lymphoma kinase , vinblastine , anaplastic large cell lymphoma , brentuximab vedotin , lymphoma , transplantation , oncology , chemotherapy , cancer research , pathology , cd30 , lung cancer , malignant pleural effusion
Vinblastine and targeted therapies induce remissions in patients with relapsed or progressive anaplastic lymphoma kinase (ALK)‐positive anaplastic large cell lymphoma (ALCL). Central nervous system (CNS) prophylaxis often is not included during re‐induction in CNS‐negative relapse patients. We report on five patients with progressive or early relapsed ALK‐positive ALCL who developed CNS progression during re‐induction with vinblastine, crizotinib, or brentuximab vedotin given for bridging to allogeneic blood stem cell transplantation. These observations suggest that CNS prophylaxis should be considered in ALCL patients suffering progression during initial therapy who receive re‐induction using agents with limited CNS penetration.